Gilead Sciences' Sovaldi Patent Application Rejected In India
January 14, 2015 at 13:08 PM EST
Gilead Sciences, Inc. (NASDAQ: GILD) patent application for its hepatitis C drug Sovaldi was rejected by the Indian patent office ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.